Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GPR81/HCAR1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GPR81/HCAR1 Recombinant Protein (Partial Extracellular Domains) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View GPR81 Products |
| Gene Delivery | GPR81/HCAR1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and GPCR conformation preservation. |
View GPR81 Products |
| Benchmark Ab | Anti-GPR81/HCAR1 Recombinant Antibody Recombinant positive control for flow cytometry and binding assays. |
View GPR81 Products |
| Validator | GPR81/HCAR1 siRNA Set For target knockdown and specificity validation. |
View GPR81 Products |
| Related Target A | HCAR2 (GPR109A) Subfamily homolog. Crucial for off-target selectivity screening to prevent flushing side effects. |
View HCAR2 Products |
| Related Target B | HCAR3 (GPR109B) Subfamily homolog. Required for counter-screening to ensure high molecular specificity. |
View HCAR3 Products |
| Related Target C | PD-L1 Synergistic pathway. GPR81 activation by lactate upregulates PD-L1 expression in the tumor microenvironment. |
View PD-L1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation Loss in Recombinant Formats | Lentivirus Premade Particles for stable cell line generation, enabling functional cell-based assays. |
| Subfamily Off-Target Cross-Reactivity (HCAR2/HCAR3) | Sequence-verified HCAR2 and HCAR3 targets available for robust counter-screening panels. |
| Lack of Reliable Reference Controls | Recombinant Benchmark Antibodies generated from clinical/literature sequences. |
| Target Validation False Positives | Sequence-specific siRNA pools for high-efficiency GPR81 knockdown verification. |
Live GPR81/HCAR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the lactate-GPR81 axis is gaining traction as a novel strategy in cancer immunotherapy and metabolic regulation. GPR81 (HCAR1) acts as a primary sensor for lactate, which is highly accumulated in the tumor microenvironment (TME) due to the Warburg effect. Activation of GPR81 on tumor cells and immune cells promotes immune evasion, angiogenesis, and chemoresistance.
The race for GPR81 therapeutics is intensifying, with major players shifting focus from traditional systemic metabolic regulators to highly localized tumor microenvironment modulators. As first-generation small molecule antagonists reach preclinical and early clinical stages, the next wave of R&D is targeting GPR81 in combination with immune checkpoint inhibitors to reverse lactate-induced immunosuppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonists | Biotech & Pharma Consortia | Solid Tumors (Pancreatic, Breast, Colon) | Functional GPCR assays (cAMP/Calcium flux) using Lentivirus-transduced stable cell lines. |
| Monoclonal Antibodies | Academic & Early-stage Biotechs | Oncology & Immunotherapy | Cell-surface binding and internalization assays requiring native conformation preservation. |
| Agonists (Metabolic) | Cardiovascular/Metabolic Developers | Dyslipidemia, Inflammation | Selectivity profiling against HCAR2/HCAR3 to prevent severe cutaneous flushing. |